MedTrace Logo

Effect of Tiotropium on Eye Findings in the Treatment of Chronic Obstructive Pulmonary Disease

NCT06525051 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 108

Last updated 2024-07-29

No results posted yet for this study

Summary

This study aimed to examine the effect of Tiotropium, which is used in the treatment of COPD, on eye symptoms.The study was conducted prospectively. Patients were examined in three groups. Thirty-six patients were included in each group in the study. Anterior chamber parameters, intraocular pressure values, and photopic-mesopic pupil diameters were measured at the initial visit for Group 1 and Group 2 patients, and at the third month of treatment for Group 3 patients.

Conditions

Interventions

DRUG

Tiotropium

Tiotropium is a long-acting anticholinergic agent and has a bronchodilator effect. According to the COPD Gold 2024 guideline, it is one of the long-acting bronchodilator drugs used as the first choice in the treatment of group A COPD patients.

Sponsors & Collaborators

  • Giresun University

    lead OTHER

Eligibility

Min Age
47 Years
Max Age
82 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-10-23
Primary Completion
2024-03-30
Completion
2024-04-30

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06525051 on ClinicalTrials.gov